Voelcker Academy

Research Symposium 2012

 

previous next
 
Johanna Lawrence

mTOR Phosphorylation after TBI in a Mouse Model

Johanna Lawrence

Mentor(s): Paul Oler, Shane Sprague, BS, David F. Jimenez, MD, FACS, Murat Digicaylioglu, MD, PhD

Mammalian Target of Rapamycin (mTOR), is a chemical that responds to changes in growth factors, nutrients, stress and energy. mTOR contains two complexes, RAPTOR and RICTOR. Rapamycin was first investigated as an anti-fungal and eventually an anti-cancer drug, and was also found to have neuroprotective abilities in a mouse model of TBI. Some possible benefits of mTOR inhibition after TBI include limited cell death, conservation of energy, and increased autophagy. The lab investigated two phosphorylation sites of interest, ser2448 and ser2481 in order to characterize mTOR phosphorylation following traumatic brain injury in a mouse model.